Tag: Stellarex DCB

New data reconfirms long-term safety profile of the Philips Stellarex low-dose Drug-Coated Balloon

June 26, 2020 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the four-year results from the ILLUMENATE European Randomized Controlled Trial (EU RCT). The Stellarex DCB cohort demonstrated similar all-cause mortality compared with the control arm through four years. This analysis included […]